Comparative Pharmacology
Head-to-head clinical analysis: NYSTATIN AND TRIAMCINOLONE ACETONIDE versus OTOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTATIN AND TRIAMCINOLONE ACETONIDE versus OTOCORT.
NYSTATIN AND TRIAMCINOLONE ACETONIDE vs OTOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vasodilation.
Otocort is a combination product containing hydrocortisone (a corticosteroid), neomycin (an aminoglycoside antibiotic), and polymyxin B (a polymyxin antibiotic). Hydrocortisone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane permeability by binding to lipopolysaccharides.
Apply thin layer to affected area twice daily for 2-4 weeks. Topical only.
1-2 drops into affected ear(s) twice daily; otic route.
None Documented
None Documented
Nystatin: not systemically absorbed; terminal half-life not applicable. Triamcinolone acetonide: after intramuscular injection, terminal half-life is approximately 2-5 hours; after topical application, minimal systemic absorption precludes meaningful half-life determination.
Hydrocortisone: plasma half-life 1.5-2 hours, biological half-life 8-12 hours due to intracellular receptor binding. Neomycin: terminal half-life 2-4 hours in patients with normal renal function; may prolong to 12-24 hours in renal impairment. Polymyxin B: terminal half-life 6-8 hours in normal renal function; significantly prolonged in renal failure (up to 2-3 days). Clinical context: Topical/otic application yields negligible systemic concentrations, so half-life is relevant only if significant absorption occurs (e.g., damaged tympanic membrane).
Nystatin: primarily excreted unchanged in feces via bile (>90%); negligible renal excretion (<1%). Triamcinolone acetonide: primarily hepatically metabolized; conjugated metabolites excreted renally (70%) and via bile (20% fecal). Systemic absorption of triamcinolone acetonide after topical application is minimal (<1%).
Otocort is a combination product containing hydrocortisone, neomycin, and polymyxin B. The corticosteroid component undergoes hepatic metabolism with renal excretion of metabolites (<5% unchanged). Neomycin is minimally absorbed (3-6% from intact skin, higher from wounds) and excreted renally as unchanged drug (30-50%) and metabolites. Polymyxin B is not significantly absorbed through intact skin or tympanic membrane; systemic absorption negligible. Renal excretion of polymyxin B is slow (40-60% over 72 hours) via glomerular filtration. Fecal elimination accounts for <5% of absorbed dose for all components.
Category D/X
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid